中廣核技(000881.SZ):子公司擬出資5億元設中廣核醫療科技
格隆匯 12 月 11日丨中廣核技(000881.SZ)公佈,公司第九屆董事會第十二次會議決議,審議通過《關於新設中廣核醫療科技有限公司(暫定名)方案的議案》;
經審議,董事會同意公司與綿陽市遊仙區人民政府簽署《中廣核核技術發展股份有限公司(綿陽)質子醫療裝備製造基地項目投資協議書》;同意由公司全資子公司中廣核達勝加速器技術有限公司出資5億元設立其全資子公司中廣核醫療科技有限公司(暫定名,以工商部門登記備案名稱為準)。
質子腫瘤治療系統是受國家食藥監局監管的三類醫療器械、受國家核安全局監管的一類射線裝置,也是受國家衞生健康委員會實施甲類配置許可監管的大型醫用設備。該業務前期培育一直依託全資子公司中廣核達勝加速器技術有限公司,但鑑於當前已經完成簽署質子治療腫瘤技術授權協議以及擬在綿陽落地質子醫療裝備製造基地,有必要將其單獨形成一個法人單位,以便取得對應的資質、適應醫療裝備製造行業的標準、規範和要求、滿足市場開發的訴求、申請產業及科研補貼,招募相應的專業人才團隊,並有針對性的制定考核目標、經營目標、發展路徑。新公司設立後,質子治療腫瘤技術授權的權利義務將完全轉移到新公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.